• 1. Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China;3. Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu 610041, China;2. Shanghai Changning Maternity & Infant Health Hospital, Shanghai 200051, China;
TANG Rongxin, Email: trx1124@126.com
Export PDF Favorites Scan Get Citation

Objective  To review the clinical evidence of Pingxiao Capsule for tumor adjuvant treatment so as to provide some decision-making references for clinical practice.
Methods  We electronically searched CBM, CNKI, VIP, WanFang Data and MEDLINE (from inception to Feb, 2013) to collect the randomized controlled trials (RCTs) and non-randomized controlled trials (non-RCTs) about Pingxiao Capsule for tumor adjuvant treatment. Then, the included studies were summarized and evaluated according to the classification of diseases.
Results  1 097 potential relevant articles were searched. We included 41 RCTs and 15 non-RCTs. The results showed that Pingxiao Capsule used as an adjuvant therapy in treating tumor improved the efficacy and reduced the side effects of radiation and chemotherapy, and also improved the quality of survival.
Conclusion  Current evidence showed that the effectiveness and safety of Pingxiao Capsule combined with radiation or chemotherapy in the tumor treatment is superior to radiation monotherapy or chemotherapy monotherapy. But due to the limited quality of the included studies, the results needed to be further verified by high-quality studies.

Citation: HUA Baojin,DU Liang,TANG Rongxin. Clinical Evidence of Pingxiao Capsule for Tumor Adjuvant Treatment. Chinese Journal of Evidence-Based Medicine, 2013, 13(8): 1018-1024. doi: 10.7507/1672-2531.20130176 Copy

  • Previous Article

    Interferon-α Combined with Lamivudine for Children with Hepatitis B: A Meta-Analysis
  • Next Article

    Report of Medical Rescue during Two Weeks after Min-Zhang Earthquake in Gansu Province